Small-cap news flow ran thick with deal-making and results updates, from a London investment shell buying into regulated Web3 payments infrastructure to an oilfield services acquisition that halted trading in an AIM oil explorer. Results season also delivered a run of upside surprises, Shoe Zone, Seeing Machines, Thor Explorations and CML Microsystems all beat expectations or reiterated guidance well enough to send shares higher, while smaller resources and biotech names logged contract wins, licensing deals and exploration milestones across the board.
Sealand takes Web3 stake in Wanel
Sealand Capital Galaxy (LSE:SCGL), the London-listed investment company, has acquired an approximately 2% minority stake in WanelCapital for £450,000 in cash, buying in alongside other investors as part of Wanel's seed funding round.
Wanel is a regulated Web3 digital financial infrastructure business operating through licensed entities in Hong Kong and Switzerland, spanning digital payments, foreign exchange, cross-border settlement, digital asset custody, treasury services and stablecoin-enabled products. Sealand shares slipped 5.76% to 0.401p on the day.
The deal complements Sealand's existing exposure to artificial intelligence, SaaS, computing infrastructure and energy-related technologies, giving it a foothold in one of Europe's established centres for regulated digital asset and payments oversight through Wanel's Swiss operations.
Beyond the equity stake, the two companies intend to explore commercial collaboration across Europe and Asia, with areas under consideration including AI-driven compliance automation, fraud detection, risk management and customer onboarding within payment systems. No timeline or financial terms have been set for any future tie-up.
"Our investment in Wanel expands Sealand's exposure to one of the most dynamic areas of financial technology," said Daniel Cao, chief executive of Sealand Capital Galaxy.
The transaction is small in absolute terms but signals intent: Sealand is positioning itself at the intersection of AI and regulated digital finance rather than committing meaningfully to any one venture yet. With no set terms for deeper collaboration, the real test will be whether the commercial partnership around compliance automation and fraud detection materialises into revenue, or whether this remains a modest financial stake dressed up as strategic positioning.
BSF Enterprise licenses ETSYL peptide to SCHAKAU
Bsf Enterprise (LSE:BSFA), the biotechnology company developing tissue engineering and bioactive materials, has agreed Heads of Terms granting SCHAKAU Managementberatung exclusive worldwide rights to commercialise its ETSYL peptide, palmitoyl pentapeptide-87, in cosmetics, skincare and luxury beauty. The shares surged 25.63% to 1.2689p on the news. Global exclusivity, full intellectual property retention for BSF and confidentiality terms become legally binding upon signature, with an initial ten-year term conditional on SCHAKAU meeting agreed annual volume targets after a 12-month ramp-up.
SCHAKAU has committed around €300,000 to fund clinical claim substantiation, regulatory filings and brand launch costs, and will separately cover all downstream compliance expenses including CPNP/SCPN filings and safety reports. BSF will supply the raw bioactive material under a dose-based volume schedule, generating manufacturing margins for its subsidiary 3D Bio-tissues. "This transaction validates our strategy of converting platform science into non-dilutive commercial cash flows," said Che Connon, chief executive of BSF Enterprise.
The structure is telling: BSF retains its IP while offloading regulatory and compliance costs onto its partner, keeping its own balance sheet light while still capturing manufacturing margin. For a small-cap biotech, a licensing deal that generates cash without diluting shareholders is a rare and welcome model, and explains the scale of the share price reaction.
Apertura agrees £25m Conterp deal, suspends listing
Apertura Energy (LSE:VZLA) has agreed heads of terms to acquire Conterp Group, a Brazilian oilfield services company, for £25m on a cash-free, debt-free basis. The AIM company's listing has been temporarily suspended while the transaction progresses, with shares last trading at 122.5p and expected to resume if the deal falls through. Conterp, based in Salvador, Brazil, has a 25-year operating history, more than 600 employees, and a signed order book exceeding £100m.
The target generated £26.4m of unaudited revenue and £3.9m of unaudited adjusted EBITDA in the twelve months to June, putting the valuation at 5.5 times current-year forecast EBITDA. Consideration splits 50% new shares and 50% cash, with Apertura planning a concurrent placing of between £10m and £30m to fund the enlarged group's growth plans.
The deal marks a pivot for a company whose strategy centres on becoming an exploration and production operator in Venezuela, where Baker Hughes recorded just two active rigs. Buying an established Brazilian services business with a large order book gives Apertura immediate revenue and operational scale while it awaits access to Venezuelan upside, a hedge against the political and logistical uncertainty inherent in that market.
Shoe Zone confirms cash ahead of budget, holds loss guidance
Shoe Zone (AIM:SHOE) said trading continued positively through July, with cash and equivalents at 25 July standing at approximately £7m, ahead of its original budget. Shares jumped 14.75% to 70.0p, with an intraday move as high as 18.9% to 72.5p, after the footwear retailer reiterated guidance for an adjusted pre-tax loss of no greater than £1m for the year ending 3 October, a figure that excludes foreign exchange gains and losses.
The update is a reiteration rather than an upgrade, but the stronger-than-budgeted cash position gives the outlook credibility. Shoe Zone's financial year runs to 3 October, meaning the current guidance covers a relatively short remaining window.
For a retailer that has been managing down expectations, confirming a loss ceiling while beating on cash is a meaningful signal of balance sheet discipline. The scale of the share reaction suggests the market had been pricing in downside risk to the cash position that simply hasn't materialised.
RentGuarantor swings to profit as revenue triples
RENTGUARANTOR HOLDINGS (RGG) swung to profit as revenue tripled, with shares easing 2.72% to 51.5575p despite the improved numbers. Chairman Graham Duncan said the growth followed implementation of the Renters' Rights Act in May, which "accelerated" demand the company had already positioned itself to capture.
The regulatory tailwind has proven more immediate than many rent-guarantee providers anticipated, giving RentGuarantor a first-mover advantage as landlords and tenants adjust to the new legislative landscape.
ECR Minerals fundraise grows amid fresh investor demand
An institutional investor has added £250,000 to Ecr Minerals (ECR)'s placing, taking total gross proceeds to £886,250 as the Australia-focused gold explorer funds work at its Maddens project. Shares dipped 2.22% to 0.176p.
The upsized raise suggests appetite for exposure to ECR's exploration pipeline is running ahead of the company's original fundraising target, even as the share price itself remains soft.
Seeing Machines posts profitable second half on royalty surge
Seeing Machines (SEE) shares rose 5.62% to 5.017p after better-than-expected results driven by surging royalties. "FY2026 was a pivotal year for Seeing Machines, with record Automotive production volumes, strong revenue growth and a profitable second half that demonstrates the operating leverage in our business," said chief executive Paul McGlone.
The shift to profitability in the second half, on the back of automotive royalty growth, marks a turning point for a company that has spent years scaling its driver-monitoring technology toward commercial payoff.
Thor Explorations posts record profit despite lower output
Thor Explorations (THX) reported record profit despite lower gold output, though shares fell 6.47% to 58.55p. The company maintained full-year production guidance of 75,000 to 85,000 ounces and all-in sustaining cost guidance of US$1,000 to US$1,200 per ounce.
The profit record, achieved even with softer output, points to strong realised gold prices offsetting operational softness, though the share price reaction suggests investors are focused more on the production shortfall than the bottom line.
Acuity RM lands prime defence contractor deal
Acuity Rm Group (ACRM), the AIM-listed cybersecurity risk software group, has signed a prime defence contractor to deploy its STREAM Classic platform, with more agreements potentially in the pipeline. Shares rose 3.7% to 0.7p.
A prime defence contractor client adds a credible reference customer in a sector known for long, rigorous procurement cycles, potentially opening doors to further defence-sector deployments.
GenIP wins string of new and repeat contracts
GenIP (TEK), the AI-driven innovation commercialisation specialist, has secured a cluster of new and recurring orders across Chile, the UK and North America. Shares gained 2.44% to 4.2p.
The geographic spread of the contract wins, spanning three continents, indicates GenIP's commercialisation model is gaining traction with repeat customers rather than relying on one-off deals.
Hemogenyx signs binding Estonia CAR-T deal
Hemogenyx Pharmaceuticals (HEMO) has signed a binding agreement with Cellin for its CAR-T therapy work in Estonia, with shares climbing 5.83% to 679.9514p. "The signing of this definitive agreement with Cellin transforms our plans in Estonia from intent into execution," said chief executive Dr Vladislav Sandler.
Moving from a non-binding intent to a definitive agreement marks a concrete step for Hemogenyx's Estonian ambitions, giving the CAR-T programme a firmer operational footing.
SysGroup lands £1m cyber contracts via Rubrik tie-up
SysGroup (SYS) has landed £1m of cyber contracts through its Rubrik partnership, with shares up 2.9% to 31.9p. "These two three-year agreements, across the social housing and further education sectors, demonstrate that this is not simply a technology partnership," said Heejae Chae.
The three-year contract terms across two distinct public-sector verticals give SysGroup visible recurring revenue and validate the Rubrik partnership as more than a reseller arrangement.
AltynGold lifts Q2 output, holds annual guidance
AltynGold (ALTN), the Kazakhstan-focused gold miner, produced 15.6koz in the second quarter as processing rates and grades recovered from a planned dip earlier in the year. Shares slipped 1.43% to 1035.0p.
The recovery in processing rates and grades keeps AltynGold on track for its annual guidance, suggesting the earlier-year dip was operational rather than a sign of deeper resource issues.
CML Microsystems flags earlier return to profitability
CML Microsystems (CML), the AIM-listed chipmaker, said order intake is running ahead of expectations, pulling forward its expected return to operational profitability. Shares jumped 9.09% to 300.0p.
An earlier-than-planned return to profitability, driven by stronger order intake, suggests demand for CML's semiconductor products is recovering faster than the company itself had budgeted.
Invinity signs EPC partner for Swiss flow battery project
Invinity Energy Systems (IES) has appointed Equans Switzerland to deliver mechanical, electrical and piping works for what it describes as the world's largest vanadium flow battery installation. Shares rose 2.47% to 22.8p.
Securing an established engineering, procurement and construction partner for a flagship project of this scale strengthens the delivery credibility of Invinity's flow battery technology at commercial size.
Optima Health tipped as a Buy ahead of results
A broker reiterated its Buy rating and 250p price target on Optima Health (OPT) ahead of next week's results, arguing the occupational health group's mid-term upside hinges on integration progress and scale benefits still to come. Shares eased 0.52% to 192.99p.
The price target implies substantial headroom above the current share price, with the broker's thesis resting on execution of integration plans that have yet to be proven out.
Verici Dx wins Olink proteomics certification
Verici Dx (VRCI), the transplant diagnostics developer, has been certified as an Olink Service Provider under Thermo Fisher's Life Sciences Solutions, adding a revenue-generating capability alongside its own biomarker pipeline. Shares surged 33.33% to 0.3p.
The certification opens a near-term services revenue stream that doesn't depend on the timeline or outcome of Verici's own diagnostic pipeline, a meaningful diversification for a small transplant-diagnostics developer.
East Star adds second rig at Verkhuba JV
East Star Resources (EST) has added a second rig as its Verkhuba joint venture hits key milestones, with shares up 2.96% to 4.17p. "These milestones complete the establishment phase of the JV and allow the partners to focus entirely on advancing Verkhuba towards resource conversion, feasibility studies and ultimately production," said chief executive Alex Walker.
Completing the establishment phase and deploying a second rig marks the project's transition from setup to active resource-definition drilling.
Synectics launches AI video search tool
Synectics (SNX) has launched its Synergy SEARCH AI video search tool, with shares up 3.44% to 201.7p. "With our first customer deployment complete, and further engagement underway, we are encouraged by the potential we see for Synergy SEARCH ahead of its full commercial launch later this year," said chief executive Amanda Larnder.
A completed first deployment ahead of full commercial launch gives Synectics an early proof point for the product before it scales sales more broadly.
Sunrise Resources secures licence over Bakers gold target
SUNRISE RESOURCES (SRES) has secured a licence over its Bakers high-grade gold target, with shares falling 7.5% to 0.0185p despite the news. "After years of impasse, our exploration rights are now secure and the Company is free to resume exploration of this exciting project," said Patrick Cheetham.
Resolving a multi-year licensing impasse clears the path for Sunrise to resume active exploration, though the negative share reaction suggests the market had already priced in the resolution or remains cautious on funding.
URU Metals finds EM anomaly aligns with nickel zone
New 3D modelling at URU Metals (URU)'s Zeb Nickel Project links its strongest electromagnetic responses to known nickel-copper-PGE mineralisation, sharpening the case for a priority drill target. Shares slipped 0.62% to 4.025p.
The alignment between geophysical anomalies and known mineralisation gives URU a data-backed rationale for its next drill target rather than a speculative one.
QBT court sets October auction for Sipiem asset
QUANTUM BLOCKCHAIN TECHNOLOGIES (QBT) said an Italian court has scheduled the sale of a confiscated property tied to its Sipiem judgment, part of a wider three-asset recovery effort. Shares traded at 0.355p.
A firm auction date gives Quantum Blockchain Technologies a concrete timeline for recovering value from the long-running Sipiem judgment, one strand of its broader asset-recovery push.
Independent study backs Parsortix tech in brain cancer
A peer-reviewed study in JCO Precision Oncology found CelLBxHealth (CLBX)'s Parsortix-enriched circulating tumour cells reflected matched tumour genomics in glioblastoma patients, aligning with the company's own internal research. Shares rose 3.7% to 1.4p.
Independent, peer-reviewed validation carries more weight with clinicians and payers than internal data alone, strengthening the credibility of Parsortix as a diagnostic tool in a notoriously hard-to-biopsy cancer.
Oriole Resources reports high-grade rock chips at Niambaram
Oriole Resources (ORR), the AIM-listed gold explorer, found rock-chip samples grading up to 28.40g/t gold at its Niambaram licence in Cameroon, while three Western Central Licence Package permits have been revoked following access disputes. Shares fell 3.88% to 0.322p.
The high-grade Niambaram results offer encouragement, but the loss of three permits elsewhere in the portfolio tempers the news and likely explains the negative share reaction.
Genedrive completes NICU recruitment for hearing test
genedrive (GDR) has finished recruiting nearly 6,000 babies to its PALOH-UK trial, clearing a key evidence hurdle as the test moves into NICE's technology appraisal process. Shares rose 1.3% to 1.165p.
Completing recruitment at this scale moves genedrive's hearing-loss test a decisive step closer to a NICE recommendation, the key gateway to NHS adoption.
Harena signs Madagascar mining terms for Ampasindava
Harena Rare Earths (HREE) has signed the Cahier des Charges Minières with Madagascar's Ministry of Mines, clearing the way to build a pilot plant at its Ampasindava rare earth project. Shares edged up 0.93% to 2.725p.
Formalising mining terms with the government removes a key regulatory obstacle, giving Harena a clear path to move from permitting into pilot-plant construction.
Afentra shares surge after Pacassa SW discovery
Afentra (AET) shares surged 10.71% to 70.3p after the Pacassa SW discovery. "The Pacassa SW discovery is a major milestone for the Block 3/05 partnership, representing the first well delivered on Block 3/05 in more than a decade," chief executive Paul McDade said.
The first successful well on the block in over ten years reopens exploration upside that had lain dormant, materially strengthening the partnership's case for further drilling.
